A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer

被引：6
|
作者：
Kwon, Daniel Hyuck-Min [1 ,2 ]
Friedlander, Terence [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
ABIRATERONE; THERAPY;
D O I：
10.21037/atm.2019.09.21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study
    T'jollyn, Huybrecht
    Ackaert, Oliver
    Chien, Caly
    Lopez-Gitlitz, Angela
    McCarthy, Sharon
    Ruixo, Carlos Perez
    Karsh, Lawrence
    Chi, Kim
    Chowdhury, Simon
    Ruixo, Juan-Jose Perez
    Agarwal, Neeraj
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 629 - 641
  • [32] Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study
    Merseburger, A. S.
    Agarwal, N.
    Bhaumik, A.
    Lefresne, F.
    Karsh, L. I.
    de Santana Gomes, A. J. Pereira
    Juarez Soto, A.
    Given, R. W.
    Brookman-May, S. D.
    Mundle, S. D.
    McCarthy, S. A.
    Uemura, H.
    Chowdhury, S.
    Chi, K. N.
    Bjartell, A.
    ONKOUROLOGIYA, 2024, 20 (01): : 79 - 93
  • [33] Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide
    Lowentritt, Benjamin H.
    Du, Shawn
    Rossi, Carmine
    Muser, Erik
    Khilfeh, Ibrahim
    Kinkead, Frederic
    Korsiak, Jill
    Lefebvre, Patrick
    Pilon, Dominic
    Agarwal, Neeraj
    FUTURE ONCOLOGY, 2024, 20 (27) : 2005 - 2013
  • [34] Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN.
    Feng, Felix Y.
    Thomas, Shibu
    Aguilar-Bonavides, Clemente
    Gormley, Michael
    Agarwal, Neeraj
    Attard, Gerhardt
    Wyatt, Alexander William
    Davicioni, Elai
    Ricci, Deborah S.
    Lopez-Gitlitz, Angela
    Larsen, Julie S.
    Chowdhury, Simon
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] How We Treat Metastatic Castration-Sensitive Prostate Cancer
    Ionescu, Filip
    Zhang, Jingsong
    CANCER CONTROL, 2024, 31
  • [36] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary B.
    Chi, Kim N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04): : 352 - 360
  • [37] Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina, Carlo
    Messina, Marco
    Boccardo, Francesco
    EUROPEAN UROLOGY, 2018, 73 (01) : 147 - 148
  • [38] Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
    Singh, Kirti
    INDIAN JOURNAL OF UROLOGY, 2023, 39 (02) : 171 - 172
  • [39] Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
    MacVicar, Gary R.
    Hussain, Maha H.
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 252 - 260
  • [40] WHAT CAN PATIENTS WITH PROSTATE CANCER EXPECT FROM TREATMENT WITH APALUTAMIDE? HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN THE PHASE 3 TITAN STUDY
    Lloyd, Jennifer
    Bevans, Katherine B.
    Dibaj, Shiva
    Brookman-May, Sabine D.
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : 23 - 23
12345